Cameron Perks – Principal Analyst – Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Copyright 2023 – Finance News Network
Source: Finance News Network
28 Feb 2024 - Graeme Sloan - Managing Director - Kali Metals (ASX:KM1) is a portfolio of assets that represents one of the largest and most prospective exploration packages across Australia’s world leading hard-rock lithium fields.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More01 Jul 2021 - Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results from the company's study of its NYX-PCSK9i cholesterol-lowering compound.
Read More25 Feb 2021 - Lake Resources Limited (ASX:LKE) Managing Director Steve Promnitz provides an update on the company's lithium brine projects in the lithium triangle of Argentina, and on its financials and strategy.
Read More07 Jul 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's portfolio of therapies.
Read More20 Mar 2023 - Magontec Limited (ASX:MGL) Executive Chairman and CEO Nicholas Andrews discusses the magnesium industry, drivers of demand, China, supply chains into the US and Europe, and recent financial results.
Read More07 Nov 2023 - Elementos Limited (ASX:ELT) Managing Director Joe David provides an update on the company's tin projects in Tasmania and Spain.
Read More06 Sep 2023 - Sequoia Financial Group Limited (ASX:SEQ) CEO and Managing Director Garry Crole discusses financial highlights, drivers of growth and revenue going forward, M&A, and cash deployment.
Read More7 July 2020 - Renergen (ASX:RLT) Managing Director, Stefano Marani talks about its high concentration of helium from Phase 1 drill results at its Virginia Gas Field in the Karoo Basin, South Africa.
Read More28 Sep 2020 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO James McBrayer provides an update on the company's US Phase 3 trial for Technegas, and USFDA approval process timeline, with commercial sales expected in the US for 2021.
Read More
